{"schemaVersion":"cwiki-fiche-2.0","identifiers":{"inchiKey":"UAHWPYUMFXYFJY-UHFFFAOYSA-N","prefName":"Mirceno","symbol":"Myrcene","iupacName":"7-méthyl-3-méthylidèneocta-1,6-diène","aliases":["β-myrcène","bêta-myrcène","myrcene","β-myrcene","β-géraniolène","7-méthyl-3-méthylène-1,6-octadiène","FEMA 2762"],"cas":"123-35-3","pubchemCid":"31253","chebiId":"CHEBI:17221","smiles":"CC(=CCCC(=C)C=C)C","molecularFormula":"C10H16","molecularWeight":136.23,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/31253","chebi":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:CHEBI:17221"}},"classification":{"family":"terpene","familyLabel":"Terpeno","origin":"plant","originLabel":"Plante","subgroup":"monoterpene","subgroupLabel":"Monoterpeno","originCode":"E","originCodeLabel":"Biosíntesis enzimática en la planta","originDebated":false,"chemicalClass":"Monoterpène acyclique (sans activité mesurée sur CB1 ni CB2)","sideChain":null,"form":null,"parent":null,"pharmacologicalClass":null,"naturalTrace":null,"structuralClassFr":null},"originSynthesis":{"heading":"Vía biosintética","summaryFr":"Monoterpeno acíclico formado a partir del pirofosfato de geranilo (GPP) por terpeno sintasas. El GPP, precursor de diez carbonos de los monoterpenos, procedente por lo general de la vía del MEP, es también un elemento de la biosíntesis de los cannabinoides (Booth 2017). En el cáñamo se han caracterizado funcionalmente dos mirceno sintasas de producto único: CsTPS3FN, de la variedad «Finola», y CsTPS30PK, de la variedad Purple Kush, que solo forman mirceno a partir del GPP y comparten apenas un 54.5 % de identidad de aminoácidos; otras terpeno sintasas del cáñamo también lo producen, entre ellas CsTPS5FN, para la que es el monoterpeno mayoritario (37 % de los productos) (Booth 2017).","originNote":"Monoterpeno muy extendido en el reino vegetal: componente principal del aceite esencial de lúpulo (NTP 2010), identificado como el principal componente analgésico del aceite esencial de hierba limón, Cymbopogon citratus (Lorenzetti 1991), y presente también en los cítricos (FDA 2018). El cáñamo lo produce por sí mismo: en las inflorescencias femeninas de 22 plantas de la variedad «Finola» representaba de media el 27 ± 21 % de los monoterpenos (Booth 2017) y, junto con el β-cariofileno y el limoneno, figura entre los tres terpenos con los contenidos medios más altos en 42 843 muestras de cannabis comercial analizadas en Estados Unidos (Smith 2022). Es un terpeno, no un cannabinoide.","discovered":""},"pharmacology":{"summaryFr":"El mirceno (β-mirceno) es un monoterpeno acíclico, uno de los terpenos más abundantes del cannabis; es un terpeno, no un cannabinoide. Tres estudios in vitro no midieron ninguna actividad directa en los receptores CB1 y CB2 humanos, ni unión, ni activación, ni modulación de la respuesta al Δ9-THC (Santiago 2019; Finlay 2020; Alayoubi 2025): estos resultados no respaldan la hipótesis de un «efecto séquito» que actúe a través de esos receptores. En animales ha mostrado efectos antinociceptivos en ratones (Rao 1990; Alayoubi 2025) y en ratas (Lorenzetti 1991; McDougall 2022), a veces bloqueados por antagonistas cannabinoides, así como efectos sedantes y miorrelajantes en ratones a 100 y 200 mg/kg por vía intraperitoneal, con una prolongación de unas 2.6 veces del sueño inducido por un barbitúrico a 200 mg/kg (do Vale 2002). In vitro activa también el canal TRPV1 (Jansen 2019). Según el National Toxicology Program no se había publicado ningún estudio de su farmacocinética en seres humanos (NTP 2010), y una revisión de 2021 señala que faltan estudios en humanos (Surendran 2021). Administrado por sonda a dosis altas durante dos años, indujo tumores renales en ratas macho y hepáticos en ratones macho (NTP 2010); el Centro Internacional de Investigaciones sobre el Cáncer lo clasificó en el grupo 2B, y en 2018 la FDA retiró el mirceno de síntesis de la lista de aromatizantes autorizados en aplicación de la cláusula Delaney, aunque consideró improbable que induzca tumores en humanos con los niveles de exposición actuales.","receptorSummaryFr":"Ninguna actividad medible en los receptores cannabinoides humanos en tres estudios in vitro. En células AtT20 que expresaban el CB1 o el CB2 humano no provocó ninguna hiperpolarización hasta 30 µM y no modificó ni la respuesta al Δ9-THC ni la respuesta al CP55,940 (Santiago 2019). A 10 µM no desplazó el [3H]CP55,940 de membranas de células HEK que expresaban el CB1 o el CB2 humano, ni modificó la señalización por AMPc, solo o asociado al Δ9-THC o al 2-AG (Finlay 2020). También a 10 µM, no activó la proteína Gi acoplada al CB1 humano en células HEK293T y no modificó ni la respuesta al CP55,940 ni las respuestas al 2-AG y a la anandamida (Alayoubi 2025). El estudio de LaVigne y cols. (2021), que describe otros terpenos del cannabis como cannabimiméticos en el CB1, no evaluó el mirceno. In vivo, sin embargo, se han descrito efectos antinociceptivos sensibles a antagonistas cannabinoides: en ratones sometidos a constricción crónica del nervio ciático, el efecto de 100 y 200 mg/kg por vía intraperitoneal fue revertido por el SR141716, antagonista del CB1 (Alayoubi 2025); en ratas con monoartritis por adyuvante de Freund, el efecto analgésico del mirceno inyectado localmente (1 y 5 mg/kg por vía subcutánea) fue bloqueado tanto por el AM281 (CB1) como por el AM630 (CB2) (McDougall 2022). Los autores de 2025 proponen una implicación indirecta del sistema endocannabinoide, que no demostraron. Fuera de los receptores cannabinoides, activa el canal TRPV1 a concentraciones micromolares en células HEK (Jansen 2019) e inhibe de forma competitiva el CYP2B1 de microsomas hepáticos de rata (Ki = 0.14 µM; De-Oliveira 1997).","binding":[{"target":"CB1","efficacy":"unknown","measure":null,"valueNm":null,"species":"humano","assay":"potencial de membrana (FLIPR), células AtT20 que expresan el CB1 humano; solo de 300 pM a 30 µM, y a 100 nM o 10 µM asociado al Δ9-THC (10 µM)","source":{"label":"Santiago et al. 2019, Cannabis Cannabinoid Res","pmid":"31559333","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/31559333/"},"strength":null,"reported":"Ninguna hiperpolarización; respuestas al Δ9-THC y al CP55,940 sin cambios","confidence":"low"},{"target":"CB2","efficacy":"unknown","measure":null,"valueNm":null,"species":"humano","assay":"potencial de membrana (FLIPR), células AtT20 que expresan el CB2 humano; solo de 300 pM a 30 µM, y a 100 nM o 10 µM asociado al Δ9-THC (10 µM)","source":{"label":"Santiago et al. 2019, Cannabis Cannabinoid Res","pmid":"31559333","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/31559333/"},"strength":null,"reported":"Ninguna hiperpolarización; respuestas al Δ9-THC y al CP55,940 sin cambios","confidence":"low"},{"target":"CB1","efficacy":"unknown","measure":null,"valueNm":null,"species":"humano","assay":"desplazamiento del [3H]CP55,940 en membranas de células HEK y AMPc (BRET CAMYEL), CB1 humano; 10 µM","source":{"label":"Finlay et al. 2020, Front Pharmacol","pmid":"32269529","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/32269529/"},"strength":null,"reported":"Sin desplazamiento del radioligando ni efecto sobre el AMPc, solo o con el Δ9-THC o el 2-AG","confidence":"low"},{"target":"CB2","efficacy":"unknown","measure":null,"valueNm":null,"species":"humano","assay":"desplazamiento del [3H]CP55,940 en membranas de células HEK y AMPc (BRET CAMYEL), CB2 humano; 10 µM","source":{"label":"Finlay et al. 2020, Front Pharmacol","pmid":"32269529","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/32269529/"},"strength":null,"reported":"Sin desplazamiento del radioligando ni efecto sobre el AMPc, solo o con el Δ9-THC o el 2-AG","confidence":"low"},{"target":"CB1","efficacy":"unknown","measure":null,"valueNm":null,"species":"humano","assay":"activación de las proteínas Gαi1 y Gαo (BRET TRUPATH), células HEK293T que expresan el CB1 humano; 10 µM","source":{"label":"Alayoubi et al. 2025, Pain","pmid":"40839768","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/40839768/"},"strength":null,"reported":"Sin activación de Gi; respuestas al CP55,940, al 2-AG y a la anandamida sin cambios","confidence":"low"},{"target":"TRPV1","efficacy":"full_agonist","measure":null,"valueNm":null,"species":"humano y rata","assay":"flujo de calcio y corrientes en patch-clamp, células HEK con expresión inducible de TRPV1 humano o de rata; respuesta inhibida por la capsazepina","source":{"label":"Jansen et al. 2019, Channels (Austin)","pmid":"31446830","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/31446830/"},"strength":null,"reported":"Activación a concentraciones micromolares (corrientes de gran amplitud a 150 µM); no se notifica ninguna CE50","confidence":"low"},{"target":"CYP2B1","efficacy":"inhibitor","measure":"Ki","valueNm":140,"species":"rata","assay":"actividad pentoxirresorufina-O-despentilasa (PROD), microsomas hepáticos de ratas tratadas con fenobarbital; inhibición competitiva (CI50 = 0,14 µM)","source":{"label":"De-Oliveira et al. 1997, Toxicol Lett","pmid":"9242356","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9242356/"},"strength":48,"reported":null,"confidence":"high"}],"references":[{"label":"Santiago M et al. Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors. Cannabis Cannabinoid Res, 2019","pmid":"31559333","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6757242/"},{"label":"Finlay DB et al. Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors. Front Pharmacol, 2020","pmid":"32269529","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7109307/"},{"label":"Alayoubi M et al. Elucidating interplay between myrcene and cannabinoid receptor 1 receptors to produce antinociception in mouse models of neuropathic pain. Pain, 2025","pmid":"40839768","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12353019/"},{"label":"LaVigne JE et al. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Sci Rep, 2021","pmid":"33859287","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8050080/"},{"label":"McDougall JJ, McKenna MK. Anti-Inflammatory and Analgesic Properties of the Cannabis Terpene Myrcene in Rat Adjuvant Monoarthritis. Int J Mol Sci, 2022","pmid":"35887239","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9319952/"},{"label":"Booth JK et al. Terpene synthases from Cannabis sativa. PLoS One, 2017","pmid":"28355238","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5371325/"},{"label":"Smith CJ et al. The phytochemical diversity of commercial Cannabis in the United States. PLoS One, 2022","pmid":"35588111","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9119530/"},{"label":"National Toxicology Program. Toxicology and carcinogenesis studies of beta-myrcene (CAS No. 123-35-3) in F344/N rats and B6C3F1 mice (gavage studies). NTP TR 557, 2010","pmid":"21415873","doi":null,"url":"https://ntp.niehs.nih.gov/sites/default/files/ntp/htdocs/lt_rpts/tr557.pdf"},{"label":"IARC Monographs Volume 119: Some Chemicals That Cause Tumours of the Urinary Tract in Rodents, 2019 (beta-mirceno, grupo 2B)","pmid":null,"doi":null,"url":"https://publications.iarc.who.int/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Some-Chemicals-That-Cause-Tumours-Of-The-Urinary-Tract-In-Rodents-2019"},{"label":"FDA. Food Additive Regulations; Synthetic Flavoring Agents and Adjuvants. Federal Register 83 FR 50490, 9 de octubre de 2018","pmid":null,"doi":null,"url":"https://www.govinfo.gov/content/pkg/FR-2018-10-09/pdf/2018-21807.pdf"},{"label":"Reglamento de Ejecución (UE) n.º 872/2012 de la Comisión, lista de la Unión de sustancias aromatizantes (n.º FL 01.008, mirceno)","pmid":null,"doi":null,"url":"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32012R0872"},{"label":"Madyastha KM, Srivatsan V. Metabolism of beta-myrcene in vivo and in vitro: its effects on rat-liver microsomal enzymes. Xenobiotica, 1987","pmid":"3604259","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/3604259/"},{"label":"De-Oliveira AC et al. In vitro inhibition of CYP2B1 monooxygenase by beta-myrcene and other monoterpenoid compounds. Toxicol Lett, 1997","pmid":"9242356","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9242356/"},{"label":"Freitas JC et al. Effect of beta-myrcene on pentobarbital sleeping time. Braz J Med Biol Res, 1993","pmid":"8257941","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/8257941/"},{"label":"Jansen C et al. Myrcene and terpene regulation of TRPV1. Channels (Austin), 2019","pmid":"31446830","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6768052/"},{"label":"Rao VS et al. Effect of myrcene on nociception in mice. J Pharm Pharmacol, 1990","pmid":"1983154","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/1983154/"},{"label":"Lorenzetti BB et al. Myrcene mimics the peripheral analgesic activity of lemongrass tea. J Ethnopharmacol, 1991","pmid":"1753786","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/1753786/"},{"label":"do Vale TG et al. Central effects of citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba. Phytomedicine, 2002","pmid":"12587690","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/12587690/"},{"label":"Delgado IF et al. Study on embryo-foetotoxicity of beta-myrcene in the rat. Food Chem Toxicol, 1993","pmid":"8444385","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/8444385/"},{"label":"Surendran S et al. Myrcene, what are the potential health benefits of this flavouring and aroma agent? Front Nutr, 2021","pmid":"34350208","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8326332/"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"state":"uncharacterised","method":"https://es.phytogrammes.com/wiki/a-propos#methode-effets","axes":[],"doseRanges":null,"humanDataCharacterised":true},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":false,"bannerTextFr":null,"toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"No listado","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-10-20","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"El mirceno está inscrito en la lista de la Unión de sustancias aromatizantes (anexo I del Reglamento (CE) n.º 1334/2008, establecida por el Reglamento de Ejecución (UE) n.º 872/2012) con el número FL 01.008, para todas las categorías de alimentos aromatizados; la nota 4 exigía datos científicos complementarios antes del 31 de diciembre de 2013, y el portal de la Comisión indica que esos datos se han presentado y que la evaluación de la EFSA está pendiente de concluir. La ECHA no le registra ninguna clasificación armonizada con arreglo al Reglamento CLP. No figura en ninguna lista de las convenciones de las Naciones Unidas de 1961 y 1971 (Lista Amarilla de la JIFE, 65.ª edición, 2026; Lista Verde, 36.ª edición, 2025).","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-10-20","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"No está clasificado como estupefaciente ni como psicótropo en Francia: el mirceno no figura ni en la lista consolidada de estupefacientes de la ANSM (actualizada el 26/06/2026), que recopila la orden del 22 de febrero de 1990 y las decisiones de la Agencia, ni en la lista consolidada de psicótropos (17/02/2026). Monoterpeno acíclico sin esqueleto cannabinoide, no entra en la clase genérica del núcleo benzo[c]cromeno (decisiones de la ANSM de 2024). Empleado como aroma, se rige por el derecho alimentario de la Unión.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-10-20","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Santiago M et al. Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors. Cannabis Cannabinoid Res, 2019","pmid":"31559333","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6757242/"},{"label":"Finlay DB et al. Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors. Front Pharmacol, 2020","pmid":"32269529","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7109307/"},{"label":"Alayoubi M et al. Elucidating interplay between myrcene and cannabinoid receptor 1 receptors to produce antinociception in mouse models of neuropathic pain. Pain, 2025","pmid":"40839768","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12353019/"},{"label":"LaVigne JE et al. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Sci Rep, 2021","pmid":"33859287","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8050080/"},{"label":"McDougall JJ, McKenna MK. Anti-Inflammatory and Analgesic Properties of the Cannabis Terpene Myrcene in Rat Adjuvant Monoarthritis. Int J Mol Sci, 2022","pmid":"35887239","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9319952/"},{"label":"Booth JK et al. Terpene synthases from Cannabis sativa. PLoS One, 2017","pmid":"28355238","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5371325/"},{"label":"Smith CJ et al. The phytochemical diversity of commercial Cannabis in the United States. PLoS One, 2022","pmid":"35588111","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9119530/"},{"label":"National Toxicology Program. Toxicology and carcinogenesis studies of beta-myrcene (CAS No. 123-35-3) in F344/N rats and B6C3F1 mice (gavage studies). NTP TR 557, 2010","pmid":"21415873","doi":null,"url":"https://ntp.niehs.nih.gov/sites/default/files/ntp/htdocs/lt_rpts/tr557.pdf"},{"label":"IARC Monographs Volume 119: Some Chemicals That Cause Tumours of the Urinary Tract in Rodents, 2019 (beta-mirceno, grupo 2B)","pmid":null,"doi":null,"url":"https://publications.iarc.who.int/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Some-Chemicals-That-Cause-Tumours-Of-The-Urinary-Tract-In-Rodents-2019"},{"label":"FDA. Food Additive Regulations; Synthetic Flavoring Agents and Adjuvants. Federal Register 83 FR 50490, 9 de octubre de 2018","pmid":null,"doi":null,"url":"https://www.govinfo.gov/content/pkg/FR-2018-10-09/pdf/2018-21807.pdf"},{"label":"Reglamento de Ejecución (UE) n.º 872/2012 de la Comisión, lista de la Unión de sustancias aromatizantes (n.º FL 01.008, mirceno)","pmid":null,"doi":null,"url":"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32012R0872"},{"label":"Madyastha KM, Srivatsan V. Metabolism of beta-myrcene in vivo and in vitro: its effects on rat-liver microsomal enzymes. Xenobiotica, 1987","pmid":"3604259","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/3604259/"},{"label":"De-Oliveira AC et al. In vitro inhibition of CYP2B1 monooxygenase by beta-myrcene and other monoterpenoid compounds. Toxicol Lett, 1997","pmid":"9242356","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9242356/"},{"label":"Freitas JC et al. Effect of beta-myrcene on pentobarbital sleeping time. Braz J Med Biol Res, 1993","pmid":"8257941","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/8257941/"},{"label":"Jansen C et al. Myrcene and terpene regulation of TRPV1. Channels (Austin), 2019","pmid":"31446830","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6768052/"},{"label":"Rao VS et al. Effect of myrcene on nociception in mice. J Pharm Pharmacol, 1990","pmid":"1983154","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/1983154/"},{"label":"Lorenzetti BB et al. Myrcene mimics the peripheral analgesic activity of lemongrass tea. J Ethnopharmacol, 1991","pmid":"1753786","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/1753786/"},{"label":"do Vale TG et al. Central effects of citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba. Phytomedicine, 2002","pmid":"12587690","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/12587690/"},{"label":"Delgado IF et al. Study on embryo-foetotoxicity of beta-myrcene in the rat. Food Chem Toxicol, 1993","pmid":"8444385","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/8444385/"},{"label":"Surendran S et al. Myrcene, what are the potential health benefits of this flavouring and aroma agent? Front Nutr, 2021","pmid":"34350208","doi":null,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8326332/"}],"meta":{"slug":"myrcene","url":"https://es.phytogrammes.com/wiki/myrcene","lastVerified":"2026-10-20","dataUpdatedAt":"2026-10-27","confidence":"high","dataCompletenessPct":80,"audit":null,"wikipedia":null,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}